

Patient Name : Demo Patient Name
Age / Sex : 56 Y / F
Referred By : DEMO HOSPITAL
Centre : HOD Head Office

Lab No : Demo Visit No
Registration On : 13-Jan-25 08:18
Patient ID : UHID.DEMO.001

Neuronal (Paraneoplastic) Autoantibodies Profile

Accession No: DEMO_BARCODE **Collected On:** 13-Jan-25 08:18 **Received On:** 13-Jan-25 11:25 **Approved On:** 14-Jan-25 21:03

Observation	Result	Unit	Biological Ref. Interval	Method
Amphiphysin	Negative			LIA
ANNA-1/HU	Negative			LIA
ANNA-2/Ri	Negative			LIA
CV2	Negative			LIA
PCA-1/YO	Negative			LIA
PNMA2 (MA2/TA)	Negative			LIA

Comments: Paraneoplastic autoimmune neurological disorders reflect a patient's humoral and cellular immune responses to cancer. Seropositive patients usually present with subacute neurological symptoms of Encephalopathy, Cerebellar ataxia, Radiculopathy, Myelopathy & Neuromuscular transmission disorders. This assay is recommended in patients with past or family history of cancer, smoking and environmental exposure to carcinogens.

Antibodies	Neurological syndrome	Typically associated tumors
Anti-Hu (ANNA 1)	<ul style="list-style-type: none"> Sensory neuropathy Chronic gastrointestinal pseudoobstruction Cerebellar degeneration Limbic encephalitis 	Small cell bronchial carcinoma
Anti-Yo (PCA1)	Cerebellar degeneration	Ovarian & Breast carcinoma
Anti-CV2	<ul style="list-style-type: none"> Chorea Sensory neuropathy Chronic gastrointestinal pseudoobstruction Cerebellar degeneration Limbic encephalitis 	Small cell bronchial carcinoma Thymoma
Anti-Ma2 (Ma/Ta)	<ul style="list-style-type: none"> Limbic encephalitis Brainstem encephalitis Cerebellar degeneration 	Seminoma, Lung carcinoma
Anti-Ri (ANNA2)	Brainstem encephalitis	Breast & Small cell bronchial carcinoma
Anti-amphiphysin	Stiff-person syndrome	Breast & Small cell bronchial carcinoma

Uses

- Serological evaluation of patients who present with a subacute neurological disorder of undetermined etiology, especially those with known risk factors for cancer
- Investigating neurological symptoms that appear in the course of, or after, cancer therapy, and are not explainable by metastasis
- To detect Occult malignancy
- Differentiating autoimmune neuropathies from neurotoxic effects of chemotherapy
- Monitoring the immune response of seropositive patients in the course of cancer therapy
- Detecting early evidence of cancer recurrence in previously seropositive patients

Remarks: Please correlate results clinically.



This is a Demo Signature
and the doctor's signature should appear here

In case of any unexpected or alarming results, please contact us immediately for re-confirmation, clarifications, and rectifications, if needed.

Scan to Validate



There may be an additional PDF attachment in this report which has been redacted for privacy. Please contact info@hod.care, if you would like to make a booking for this test.